A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

Adavosertib selectively inhibits Wee1, which regulates intra-S and G2/M cell-cycle checkpoints. This study investigated dosing schedules for adavosertib monotherapy, determining the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in patients with advanced solid tumors. Patients rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Falchook, Gerald S, Sachdev, Jasgit, Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh M, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David R, Johnson, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289903/
https://www.ncbi.nlm.nih.gov/pubmed/37171722
http://dx.doi.org/10.1007/s10637-023-01371-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289903/
https://www.ncbi.nlm.nih.gov/pubmed/37171722
http://dx.doi.org/10.1007/s10637-023-01371-6

Ejemplares similares